Cardiology

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  

Retrieved on: 
Wednesday, April 10, 2024
Consensus, Glaucoma, Conditional sentence, University, Finance, RMB, Risk, Approximation error, Patient, Artificial intelligence, Medical device, National Health Commission, Optometry, Endocrinology, Dementia, Certification, Hyperthyroidism, Ageing, Capital Medical University, Software, MICCAI, Hypertensive retinopathy, Beijing Tongren Hospital, Neurology, Acceleration, Intelligence, Paratriathlon, Hospital, Research, Near-sightedness, Amblyopia, AI, MDR, Strabismus, Skin, AMD, Ranibizumab, Diagnosis, Peking University, Growth, Cardiology, Physical examination, News, Cataract, Diabetic retinopathy, Ophthalmology

In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points: 
  • In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.
  • 2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
  • Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
  • In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

Hong Kong Ferry announces FY2023 annual results Increase in revenue for FY2023 Sales on completed existing units of The Symphonie

Retrieved on: 
Wednesday, April 10, 2024
Health, Shipyard, Consolidated, Urology, Cardiology, Patient, ICON, Spectacle, Sale, Transport Department, Seemabaddha, Tung, Point, HK25, Holding, Rheumatology, Elective surgery, Mira Place, Property management

Consolidated profit after taxation for FY2023 amounted to HK$186 million, down by approximately 86% as compared to last year.

Key Points: 
  • Consolidated profit after taxation for FY2023 amounted to HK$186 million, down by approximately 86% as compared to last year.
  • （22 March 2024, Hong Kong） – Hong Kong Ferry (Holdings) Company Limited (the “Company”, which together with its subsidiaries, is referred to as the “Group”; SEHK stock code: 0050) announced annual results for the year ended 31 December 2023.
  • The revenue and operating profit for the year were mainly derived from the rental income from shops and commercial arcades as well as interest income from banks.
  • Mr. Gabriel Lee, General Manager of Hong Kong Ferry, said, “The Hong Kong Ferry Group has been established for 100 years in 2023, and the Group has successfully transformed itself from a ferry and shipyard focused business into an integrated conglomerate.

EQS-News: MEDICLIN plans to buy Reha-Klinik am Sendesaal

Retrieved on: 
Wednesday, April 10, 2024
Region, Commercial director, Geriatrics, Bed, Cardiology, Rehabilitation, Hospital

Offenburg, 22 March 2024: MEDICLIN is about to purchase the Reha-Klinik am Sendesaal in Bremen, which currently belongs to the Specht Group.

Key Points: 
  • Offenburg, 22 March 2024: MEDICLIN is about to purchase the Reha-Klinik am Sendesaal in Bremen, which currently belongs to the Specht Group.
  • In a joint staff meeting today, the clinic's employees were informed in person about the expected changes.
  • Kammann, who is also Commercial Director of the MEDICLIN Hedon Clinic in Lingen, will also manage the rehabilitation clinic to be bought in future.
  • Reha-Klinik am Sendesaal is an interdisciplinary clinic for stationary and ambulatory rehabilitation with the indications cardiology, orthopaedics and geriatrics.

Cardiol Therapeutics Announces Year-End 2023 Update on Operations

Retrieved on: 
Tuesday, April 2, 2024
Hypertrophy, Heart, CRDL, Patient, Mayo Clinic, PPAR, Agent handling, Cleveland Clinic, Fibrosis, European, Therapy, Myocarditis, Analysis, American Heart Association, Human, Massachusetts General Hospital, Pericarditis, MMT, Heart failure, American College, Safety, ODD, Cardiology, Clinical professor, Disease, Pericardium, Research, World Heart Federation, Management, University, Death, Pericardial effusion, Maverick, Reactive oxygen species, TSX, Priority review, FDA, Conversation, Financial statement, Inflammation, Fast Track, Calcium, Wound healing, API, Pharmaceutical industry

"Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.

Key Points: 
  • "Cardiol Therapeutics made important progress in 2023 and early 2024 as we pursued our primary objective of providing new therapeutic options to patients with poorly served heart diseases," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics.
  • In January 2023, Cardiol announced the first patient had been enrolled in the Company's Phase II open-label pilot study ("MAvERIC-Pilot") investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis.
  • In November 2023, Cardiol announced that it had exceeded 50% of the patient enrollment target for the MAvERIC-Pilot study.
  • In January 2024, Cardiol announced that ARCHER had exceeded 50% patient enrollment and was progressing ahead of the original study timeline.

Powerful Medical's AI Breakthrough Marks a New Dawn in Heart Attack Diagnostics with EIC Support Doubles Sensitivity in Identifying Acute Coronary Occlusion on 12-Lead ECG

Retrieved on: 
Monday, March 18, 2024
European Innovation Council, Longevity, Medicine, Cardiology, Patient, Splenic infarction, MD, EIC, Accelerator, European Investment Bank, Heart, EIB, FDA, Health, Medical device

With a landmark advancement in medical diagnostics, Powerful Medical has distinguished itself within the competitive digital health landscape.

Key Points: 
  • With a landmark advancement in medical diagnostics, Powerful Medical has distinguished itself within the competitive digital health landscape.
  • At the core of its mission, Powerful Medical introduces the PMcardio platform, a CE-certified medical device leveraging proprietary AI to analyze electrocardiograms (ECGs) with remarkable precision.
  • This platform is capable of diagnosing heart attacks — specifically, occlusion myocardial infarctions — significantly earlier and with double the sensitivity compared to the current standard of care.
  • - Robert Herman, MD, Chief Medical Officer
    As Powerful Medical begins its Series A fundraising, the EIC Accelerator's grant and investment endorse the company's vision and technology.

Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, X-ray, LTD, Cardiology, Patient, Science, Radiology, SCL, Department of Tourism (Philippines), NANO, Teleradiology, ARC, Marketing, Medical device

PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox artificial intelligence (AI) solutions in Korea with AhealthZ – a distributor of healthcare services and devices – and SCL Science, AhealthZ’s affiliated company and subsidiary of global healthcare group SCL (Seoul Clinical Laboratories).

Key Points: 
  • Under the collaboration, AhealthZ plans to assist Nanox in efforts to secure local authorizations and licenses to enable the importation, marketing and sales of the Nanox.ARC in South Korea.
  • The Nanox.ARC is a digital tomosynthesis system that uses multiple sources of X-rays to produce a three-dimensional, tomographic images.
  • The collaboration will also include SCL Science integrating Nanox’s AI solutions in remote image analysis and other operations.
  • “We are excited to work with AhealthZ and SCL Science to bring our comprehensive medical imaging solutions to South Korea, a country of over 51 million people and one of the world’s most advanced technological markets,” said Erez Meltzer, Nanox Chief Executive Officer.

Sutter Health Announces Significant Investment in a New Advanced Multi-Specialty Neurosciences Care Complex in San Francisco’s Mission Neighborhood

Retrieved on: 
Thursday, April 4, 2024
Neurology, Diagnosis, Brain, Cardiology, Partnership, Physician, Health, Patient, SAN, Stroke, Research, Aneurysm, Elective surgery, Sutter Health, General surgery, Forbes Norris, Neurosurgery, Investment, Pediatrics, Hospital, Endocrinology, Podiatry, Graduate medical education, Rehabilitation, Nursing

The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.

Key Points: 
  • The new Mission Bernal Care Complex, built on the site of the former St. Luke’s Hospital, will serve as an advanced, multi-specialty center for comprehensive neurological and neurosurgical care.
  • Finally, Sutter will expand primary care and women’s care services on the Mission Bernal Campus at the Monteagle building ( 1580 Valencia St .).
  • "At Sutter Health, the commitment to expanding access to high-quality care is unstoppable,” said Ken McNeely, Sutter Health board chair.
  • “This investment underscores the organization's dedication to meeting the health care needs of Northern California communities, ensuring that patients receive exceptional care close to home.

OneMedNet Completes Securities Purchase Agreement, Solidifying Cash Position to Accelerate Growth

Retrieved on: 
Tuesday, April 2, 2024
Real, ARC, Growth, Note, Sale, Research, Cardiology

OneMedNet intends to use the net proceeds when received from the offering for working capital purposes.

Key Points: 
  • OneMedNet intends to use the net proceeds when received from the offering for working capital purposes.
  • “This Securities Purchase Agreement demonstrates confidence in our comprehensive iRWD™ platform, marking an important milestone for OneMedNet as we have the investment needed to expedite our growth, enhance our network, and propel the development of our AI-driven solutions.
  • Our platform is designed to meet the clinical requirements necessary across various domains, including but not limited to rare diseases, oncology, and cardiology.
  • acted as legal counsel to OneMedNet Corporation on the Notes Offering and Lucosky Brookman LLP acted as legal counsel to the Investor.

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
Independent, Business school, Bachelor of Science, Engineering, Bristol Myers Squibb, Thayer School of Engineering, Immunology, Therapy, Corporate development, Corporation, True north, ICON PLC, Business, Dartmouth College, Biogen, ATP, Genzyme, Cardiology, Biomedical engineering, Novo Nordisk, Drug discovery, Tuck School of Business, Acquisition, University, MBBS, AbbVie, Bioverativ, ICON, CBO, Columbia University, Biology, MBA, Hidradenitis suppurativa, TRML, Partner, Military, Management

The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.

Key Points: 
  • The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development.
  • The recent board appointments include Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent Directors.
  • He has spent over a decade specializing in founding, building and investing in biotech companies.
  • Samantha also chairs the Board of Advisors for Thayer School of Engineering at Dartmouth and is a member of the Board of Advisors for Life Science Cares.

Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24

Retrieved on: 
Monday, April 1, 2024
Cardiology, Congress Center, BVA, American College, Booth

Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 – 8, 2024.

Key Points: 
  • Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 – 8, 2024.
  • “ACC.24 is considered the premier cardiology exposition in the Americas, offering a prime opportunity for Daxor to broaden its reach within the entire cardiovascular community,” said Michael Feldschuh, Daxor’s CEO and President.
  • “This conference presents an ideal platform for engaging with healthcare providers for whom effective volume management poses a significant challenge.
  • Our blood volume analysis (BVA) technology provides 98% accurate, actionable data to optimize treatment plans and personalize care, improving outcomes while reducing duration and cost of care.”
    The Company will be exhibiting at Booth #2312.